Table 2. | Personal and clinical characteristics of patients with MRONJ and treatment received (n = 3) |
| Case | Sex | Age | Antiresorptive agent | Indication for treatment | Treatment duration (years) | Lesion site | Stage AAOM | Triggering factor | Treatment for MRONJ | Follow-up outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 77 | Ibandronic acid (alendronate) | Osteoporosis | (5) + 1 | Mandible | 2 | Implant removal due to perimplantitis | Surgical debridement | Good wound healing, paraesthesia remained |
| 2 | F | 66 | Denosumab | Bone metastases (breast cancer) | 1 | Mandible | 2 | Dental extraction |
Surgical debridement + PRF |
Good wound healing, remained discomfort (NRS = 3) |
| 3 | F | 80 | Ibandronic acid | Osteoporosis | 8 | Mandible | 2 | Dental extraction |
Surgical debridement + Er:YAG laser |
Good wound healing, no more paraesthesia |
AAOM = American Association of Oral and Maxillofacial Surgeons; MRONJ = medication-related osteonecrosis of the jaw; F = female; PRF = platelet-rich fibrin; NRS = numeric rating scale. |
.png)